Periorbital Hyperpigmentatio.
Conditions
Interventions
Intervention 1: Intervention group: Application of a periorbital brightening cream or gel for 8 weeks, twice daily in the morning and evening. Intervention 2: Control group: Application of a placebo g
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: VAS score = 4 Men and women aged 20–50 years with bilateral periorbital hyperpigmentation (VAS) Patients presenting to the Dermatology Clinic of Imam Khomeini Hospital, Ahvaz Informed consent and signed consent form No history of similar treatment (laser, injection, topical medication) in the past 6 months
Exclusion criteria
Exclusion criteria: History of similar treatment (laser, injection, topical medication) in the past 6 months Active dermatologic or infectious disease in the periorbital area Allergy or hypersensitivity to study medications Pregnancy or breastfeeding Severe systemic disease that may endanger participant safety
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Periorbital hyperpigmentation severity measured by the **Visual Analog Scale (VAS). Timepoint: Periorbital hyperpigmentation and other outcomes are measured at **baseline (before treatment) and during follow-ups at weeks 2, 4, and 6. Method of measurement: Periorbital hyperpigmentation severity is assessed by a physician using the **Visual Analog Scale (VAS)**. Patient quality of life is measured using the **Dermatology Life Quality Index (DLQI)**, and procedural pain is recorded using the **Pain Scale 0–10**. Serial photographs of the affected areas are taken for objective assessment and comparison before and after treatment. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNader Paziar
Ahvaz University of Medical Sciences
Outcome results
None listed